Pipeline

제넥신은 혁신적인 바이오 신약과 다양한 바이오베터를 개발하고 있습니다. 특히 희귀질병, 암 및 면역 질환 분야의 치료제 개발에 집중하고 있습니다.

HyLeukin-7 (rhIL-7-hyFc)

Areas Indication Regimen Research Pre-Clinical Clinical Phase Site
I II III
정상인 SAD
 
 
KR
면역항암 고형암 Mono
 
 
KR
Mono (I-Mab)
 
 
CN
Cyclophosphamide 병용
 
 
KR
교모세포종 Mono
 
 
KR/US
TMZ 병용
 
 
US
TMZ 병용
 
 
CN
삼중음성유방암 Pembrolizumab 병용
 
 
KR
피부암 Atezolizumab 병용
 
 
US

HyTropin (long-acting hGH, GX-H9)

Indication Research Pre-Clinical Clinical Phase Site
I II III
성인 성장호르몬결핍증
 
 
EU/KR/CN
소아 성장호르몬결핍증
 
 

HyPoietin (long-acting EPO, GX-E4)

Indication Research Pre-Clinical Clinical Phase Site
I II III
만성 신부전증에 의한 빈혈
 
 
ASEAN/EU

HyGrastim (long-acting G-CSF, GX-G3)

Indication Research Pre-Clinical Clinical Phase Site
I II III
호중구감소증
 
 
KR/EU

HyGlutide (long-acting GLP-1, GX-G6)

Indication Research Pre-Clinical Clinical Phase Site
I II III
제2형 당뇨
 
 
AUS

GX-G8 (Long-acting GLP-2)

Areas Indication Research Pre-Clinical Clinical Phase Site
I II III
단장증후군
 
 
EU

Papitrol-188 (HPV DNA Vaccine)

Indication Regimen Research Pre-Clinical Clinical Phase Site
I II III
자궁경부전암
단독투여
 
 
KR/EU
자궁경부암 Pembrolizumab 병용투여
 
 
KR

GX-P1 (Long-acting PD-L1)

Areas Indication Research Pre-Clinical Clinical Phase Site
I II III
자가면역질환
 
 
KR

GX-P10 (Long-acting PD-L1-IL10)

Areas Indication Research Pre-Clinical Clinical Phase Site
I II III
간이식
 
 
KR

Multi-Target Antibody Drug Candidates

Areas Indication Research Pre-Clinical Clinical Phase Site
I II III
Multi-Specific
(Bi-, Tri-)
 
 
KR

GX-19 (COVID-19-DNA Vaccine)

Areas Indication Research Pre-Clinical Clinical Phase Site
I II III
COVID-19
 
 
KR